Partner Content
Category :
Partner Content
/
Press releases
Newsletters and Deep Dive digital magazine
With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers.
As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and peer-to-peer communication. That means going beyond TV ad celebrities or one-off Instagram relationships limited to short-term PR value.
When it comes to motivating consumers to take action with their health, and especially inspiring people to speak to a doctor, pharma needs to be thinking about new ways not just to reach patients but to activate them.
Social health—the digital means by which health consumers engage with each other and their health—has broad applications for the healthcare industry overall. To learn more, read the full article on health-union.com.
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regul
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox